Study to Evaluate DNL151 in Subjects With Parkinson's Disease
Status:
Completed
Trial end date:
2020-12-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and
pharmacodynamics of multiple oral doses of DNL151 in subjects with Parkinson's disease.